• Psyence BioMed welcomed reports that U.S. administration is preparing an executive order to evaluate ibogaine safety and therapeutic potential.
• CEO Jody Aufrichtig backed structured, evidence-based research to clarify ibogaine safety, efficacy, and role in clinical care.
• Psyence BioMed flagged ibogaine’s Schedule I status in U.S., citing patient access through unregulated settings outside country.
• Company highlighted GMP-compliant ibogaine manufacturing capabilities through PsyLabs to support global clinical research.
• Psyence BioMed reiterated development of an ethically sourced supply chain in Africa to support standardized ibogaine availability as regulation evolves.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604170915PRIMZONEFULLFEED9691981) on April 17, 2026, and is solely responsible for the information contained therein.